Ligand Pharmaceuticals (LGND) Amortization - Intangibles (2015 - 2026)

Ligand Pharmaceuticals has disclosed Amortization - Intangibles across 12 years of filings, most recently posting $8.1 million for Q1 2026.

• Amortization - Intangibles for Q1 2026 came in at $8.1 million, down 1.94% year-over-year; the trailing twelve-month figure through Mar 2026 was $32.5 million (down 1.61% YoY), and the FY2025 annual result was $32.7 million, down 0.91% from the prior year.
• Amortization - Intangibles came in at $8.1 million for Q1 2026 at Ligand Pharmaceuticals, roughly flat from $8.1 million in the prior quarter.
• In the past five years, Amortization - Intangibles ranged from a high of $8.6 million in Q1 2022 to a low of $8.1 million in Q4 2025.
• The 5-year median for Amortization - Intangibles is $8.3 million (2024), against an average of $8.3 million.
• Peak annual rise in Amortization - Intangibles reached 813.85% in 2022, while the deepest fall reached 27.56% in 2022.
• Ligand Pharmaceuticals' Amortization - Intangibles stood at $8.5 million in 2022, then fell by 1.93% to $8.3 million in 2023, then dropped by 0.47% to $8.3 million in 2024, then declined by 2.54% to $8.1 million in 2025, then advanced by 0.11% to $8.1 million in 2026.
• The last three Amortization - Intangibles figures came in at $8.1 million (Q1 2026), $8.1 million (Q4 2025), and $8.1 million (Q3 2025), per Business Quant data.